Treatment for severe sepsis using immune cell therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a novel therapy for patients suffering from severe sepsis. Participants will be randomized into a treatment group that receives an immune cell perfusion system in addition to standard care. The aim is to enhance immune competence and improve organ function in patients experiencing septic shock. The study focuses on adults who meet specific criteria related to their condition and treatment needs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult subjects

   1. ≥ 18 years of age
   2. with septic shock, defined as those with septic shock according to" Sepsis-3-Definition" who additionally require norepinephrine at a dose of ≥ 0.15 mcg/kg/min (and/or vasopressin at any dose) for a minimum of 6 hours (within the last 48 hours), to maintain a MAP ≥65 mmHg
   3. Subjects ≥ 80 years of age shall have a Clinical Frailty Scale of \<5 to be enrolled.
2. Fulfillment of the definition of septic shock, not longer than 48h before randomization. I.e. the 48h start at the end of the 6h period.
3. Blood lactate \>2 mmol/L despite adequate volume resuscitation during the current sepsis episode
4. Source control achieved / in progress in the judgement of the investigator
5. Subjects are required to have central venous access and an arterial line, and these are expected to remain present for at least the initial 48 hours of study.
6. Subjects must have received adequate volume replacement in the judgement of the investigator.
7. Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or confirmation of the urgency of participation in the clinical trial and the possible benefit to the subject by an independent consultant or the implementation of other established procedures according to the local regulations of the contributing centre to include subjects who are unable to provide informed consent.

Exclusion Criteria:

1. Acute or chronic leukemia,
2. Bilirubin ≥ 2 mg/dL (≥33 µmol/L),
3. Ongoing (concomitant) or prior within the last 6 month any chemotherapy or radiotherapy for malignancy,
4. Autoimmune disease with systemic medication of ≥10 mg prednisolone equivalent,
5. Previous transplantation,
6. Subjects receiving interferon therapy (14 days prior randomisation),
7. Acute pulmonary embolism within the last 72 hours,
8. Ischemic stroke or intracranial bleeding within the last 3 months
9. Suspicion of concomitant acute coronary syndrome based on clinical symptoms and/or ECG within the last 72 hours,
10. Cardiopulmonary resuscitation within last 7 days,
11. Moribund subject (life expectancy \<72 hours), in the judgement of the investigator
12. Presence of a do-not-resuscitate or do-not-intubate order,
13. Known HIV infection or chronic viral hepatitis,
14. Isolated Urosepsis,
15. Pregnancy/nursing period,
16. Primary cause of hypotension not due to sepsis (e.g. major trauma including traumatic brain injury, haemorrhage, burns, or congestive heart failure/cardiogenic shock),
17. Previous sepsis with ICU admission within this hospital stay,
18. Known/suspected acute mesenteric ischaemia,
19. Chronic mechanical ventilation for any reason OR severe COPD requiring either continuous daily oxygen use during the preceding 30 days or mechanical ventilation (for acute exacerbation of COPD) during the preceding 30 days,
20. Decision to limit full care taken before obtaining informed consent,
21. Prior enrolment in the trial,
22. Prior use of an investigational medicinal product within the last month OR planned or concurrent participation in a clinical trial for any investigational drug or device,
23. multiple injuries including polytrauma and burn \>20% TBSA (2° or 3°),
24. Diagnosed and documented pre-existing dementia,
25. Severe Covid-Pneumonia

Where it's running

• Universitätsklinikum Regensburg, Klinik für Anästhesiologie
  Regensburg, Bavaria, Germany Recruiting
• Universitätsklinikum Bonn, Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin
  Bonn, North Rhine-Westphalia, Germany Recruiting
• Universitätsklinikum Köln, Klinik für Anästhesiologie und Operative Intensivmedizin
  Cologne, North Rhine-Westphalia, Germany Recruiting
• Helios Klinikum Aue
  Aue, Saxony, Germany Recruiting
• Universitätsklinikum Leipzig, Klinik und PK für Anästhesiologie und Intensivtherapie
  Leipzig, Saxony, Germany Recruiting
• Universitätsklinikum Halle (Saale), Universitätsklinik für Anästhesiologie und Operative Intensivmedizin
  Halle, Saxony-Anhalt, Germany Recruiting

Study contacts

• Principal investigator: Daniel Reuter, Prof.Dr. — University Hospital Rostock
• Study coordinator: Jens Altrichter, MD
• Email: jens.altrichter@artcline.de
• Phone: +49 381-440-703

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating how transposable elements affect immune aging in sepsis patients

  This study looks at how certain genetic elements might affect the immune system and health outcomes in people with sepsis in the ICU.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06809868

• Identifying biomarkers for diagnosing sepsis in the emergency room

  This study is trying to find out if certain immune responses can help doctors spot sepsis in patients with infections when they arrive at the emergency room.

  Recruiting at 2 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Almere Stad, Flevoland and 2 other locations · NCT06178822

• Reducing unnecessary vancomycin use in children with suspected sepsis

  This study is testing a new approach to see if better guidelines and education can help doctors use less vancomycin in children suspected of having sepsis, which could lower the risk of kidney problems.

  Recruiting at 4 sites Children's Hospital of Philadelphia · Atlanta, Georgia and 3 other locations · NCT05975671

• Early use of norepinephrine for treating severe sepsis

  This study is testing if giving norepinephrine earlier can help people with severe sepsis feel better and live longer compared to a placebo.

  Recruiting Phase 4 Tunis University · Tunis · NCT05836272

• Evaluating sepsis treatment methods in emergency departments

  This study tests two different treatment plans for sepsis in emergency rooms to see which one helps patients survive and avoid breathing problems better.

  Recruiting Rhode Island Hospital · Providence, Rhode Island · NCT05491941

• Using gamma globulin to treat critically ill children with inflammatory storms

  This study is testing if gamma globulin therapy can help critically ill children with severe inflammatory conditions recover better than those who don’t receive it.

  Recruiting at 2 sites Children's Hospital of Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT04850456

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.